CLINICAL_TRIALS ClinicalTrials.gov record update

Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03012620
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:56.840014+00:00
Published At: 2024-02-28T00:00:00+00:00
Record Updated At: 2024-02-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Sarcoma", "Ovarian Neoplasm", "Central Nervous System Neoplasm", "Thyroid Neoplasm", "Carcinoma, Neuroendocrine", "Neoplasms, Germ Cell and Embryonal", "NK/T-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-02-28"
protocolSection.identificationModule.nctId: "NCT03012620"
protocolSection.identificationModule.officialTitle: "Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.